CBD oil improved autistic behaviors and reduced brain oxidative stress in a mouse model

In a valproic acid-induced autism mouse model, CBD oil (100 mg/kg/day orally for 3 weeks starting at postnatal day 21) improved autistic behaviors including anxiety, delayed response to painful stimuli, and impaired social interaction. Biochemical analysis showed CBD oil restored depleted glutathione and antioxidant levels. Morphological staining revealed improvements in the hippocampus, prefrontal cortex, and Purkinje cells. CBD oil performed comparably to the standard antipsychotic risperidone (0.5 mg/kg/day).

VPA-induced autism mouse model using BALB/c mice exposed to valproic acid (600 mg/kg) on gestational day 13. Male pups divided at postnatal day 21 into four groups: control saline, VPA-exposed, VPA + CBD oil (100 mg/kg/day), and VPA + risperidone (0.5 mg/kg/day) for 3 weeks. Behavioral, biochemical, and histological analyses performed.

Autism spectrum disorder currently has no effective treatment for core symptoms. Preclinical evidence that CBD oil addresses both behavioral and neurobiological aspects of autism through antioxidant mechanisms could inform future clinical research, though animal models of autism have significant translational limitations.

Interest in cannabidiol for autism has grown rapidly, with some clinical trials underway. This preclinical study suggests the mechanism may involve antioxidant pathways rather than direct cannabinoid receptor effects, which could guide clinical trial design and outcome measures.

Animal model of autism has significant limitations in replicating human ASD. Only male pups studied. Single dose of CBD oil tested. VPA-induced autism model represents only one possible etiology. Short treatment duration. Translating mouse doses to human equivalents is uncertain.